首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   587篇
  免费   51篇
  国内免费   5篇
  643篇
  2024年   2篇
  2023年   21篇
  2022年   13篇
  2021年   15篇
  2020年   25篇
  2019年   32篇
  2018年   29篇
  2017年   16篇
  2016年   30篇
  2015年   21篇
  2014年   52篇
  2013年   41篇
  2012年   29篇
  2011年   28篇
  2010年   12篇
  2009年   20篇
  2008年   18篇
  2007年   25篇
  2006年   19篇
  2005年   21篇
  2004年   13篇
  2003年   17篇
  2002年   9篇
  2001年   15篇
  2000年   7篇
  1999年   20篇
  1998年   4篇
  1997年   6篇
  1996年   3篇
  1995年   5篇
  1994年   12篇
  1993年   4篇
  1992年   2篇
  1991年   8篇
  1990年   4篇
  1989年   6篇
  1988年   7篇
  1987年   4篇
  1986年   6篇
  1985年   4篇
  1984年   1篇
  1983年   3篇
  1982年   2篇
  1981年   1篇
  1977年   1篇
  1975年   3篇
  1974年   1篇
  1973年   2篇
  1972年   3篇
  1971年   1篇
排序方式: 共有643条查询结果,搜索用时 15 毫秒
1.
Sequential medical trials involving paired data   总被引:2,自引:0,他引:2  
  相似文献   
2.
Full and reduced models for yield trials   总被引:2,自引:0,他引:2  
Summary Empirical results routinely demonstrate that the reduced Additive Main effects and Multiplicative Interaction (AMMI) model achieves better predictive accuracy for yield trials than does the full treatment means model. It may seem mysterious that treatment means are not the most accurate estimates, but rather that the AMMI model is often more accurate than its data. The statistical explanation involves the Stein effect, whereby a small sacrifice in bias can produce a large gain in accuracy. The corresponding agricultural explanation is somewhat complex, beginning with a yield trial's design and ending with its research purposes and applications. In essence, AMMI selectively recovers pattern related to the treatment design in its model, while selectively relegating noise related to the experimental design in its discarded residual. For estimating the yield of a particular genotype in a particular environment, the AMMI model uses the entire yield trial, rather than only the several replications of this particular trial, as in the treatment means model. This use of more information is the source of AMMI's gain in accuracy.This research was supported by the Rhizobotany Project of the USDA-ARS  相似文献   
3.
Criteria for the evaluation of new drugs to treat obesity are important as guides for designing clinical trials to test these agents. These criteria must be developed in relation to the realities of obesity, which is a chronic disease associated with morbidity and mortality that is increased by visceral fat deposits. The observation that patients regain weight after stopping drug treatment for obesity argues for the proposition that drugs work only when taken and NOT that the drugs are ineffective. The analogy between the development of treatments for obesity to those for the treatment of hypertension is used to highlight potential areas for new developments. Several features of an ideal drug for the treatment of obesity are suggested. Criteria for evaluating new drugs include both primary and secondary endpoints. The primary endpoint for an anti-obesity drug should be weight loss, possibly by category of success. Losses of total body fat or visceral fat might be alternative primary endpoints. Secondary endpoints include reduction in risk factors for associated diseases and improvement in the quality of life. In trials where vigorous placebo designs including highly aggressive behavior modification or very-low-calorie diets were used, it may be difficult or impossible to detect a response to a drug.  相似文献   
4.
There is increasing amount of evidence indicating the close interplays between the replication cycle of SARS-CoV-2 and the autophagy-lysosome pathway in the host cells. While autophagy machinery is known to either assist or inhibit the viral replication process, the reciprocal effects of the SARS-CoV-2 on the autophagy-lysosome pathway have also been increasingly appreciated. More importantly, despite the disappointing results from the clinical trials of chloroquine and hydroxychloroquine in treatment of COVID-19, there is still ongoing effort in discovering new therapeutics targeting the autophagy-lysosome pathway. In this review, we provide an update-to-date summary of the interplays between the autophagy-lysosome pathway in the host cells and the pathogen SARS-CoV-2 at the molecular level, to highlight the prognostic value of autophagy markers in COVID-19 patients and to discuss the potential of developing novel therapeutic strategies for COVID-19 by targeting the autophagy-lysosome pathway. Thus, understanding the nature of such interactions between SARS-CoV-2 and the autophagy-lysosome pathway in the host cells is expected to provide novel strategies in battling against this global pandemic.  相似文献   
5.
新型疫苗佐剂的研究进展   总被引:3,自引:0,他引:3  
与传统的灭活或活体疫苗相比,由基因工程重组抗原或化学合成多肽组成的现代疫苗往往存在免疫原性弱等问题,需要新型的免疫佐剂来增强其作用。尽管传统的铝盐佐剂是目前唯一全球公认的人用佐剂,但存在激发细胞免疫应答能力差等不足,因此,需要研发更为安全有效的人用新型佐剂,尤其是安全无毒、能够刺激较强细胞免疫应答的佐剂,以及适合粘膜疫苗、DNA疫苗和癌症疫苗的免疫佐剂。分析阐述了新型佐剂研究状况和佐剂发展方向,并进一步对新型佐剂的临床前和临床试验研究以及已批准上市的新型疫苗佐剂进行了综述。  相似文献   
6.
Changes in soil structure and in microbial population were recorded in a long term field experiment over the growing season of maize (June–November). Determinations were made on samples from plots which had received, for two years, the following treatments: mineral fertilizers, farmyard manure and three rates of compost. Seasonal variations were observed for the stability of soil aggregates, total porosity, pore size distribution, mycorrhizal infection and aerobic cellulolytic microorganisms. The stability of the soil aggregates changed in a similar way to that found for both mycorrhizal infection and the number of aerobic cellulolytic microorganisms. Physical characteristics were not affected in any instance by the organic dressings and microbiological populations were generally influenced only by the higher doses of compost.  相似文献   
7.
Randomization models for the matched and unmatched 2 ? 2 tables   总被引:1,自引:0,他引:1  
COPAS  J. B. 《Biometrika》1973,60(3):467-476
  相似文献   
8.
Pneumonia is the inflammation of the lungs and it is the world’s leading cause of death for children under 5 years of age.The latest coronavirus disease 2019(COVID-19)virus is a prominent culprit to severe pneumonia.With the pandemic running rampant for the past year,more than 1590000 deaths has occurred worldwide up to December 2020 and are substantially attributable to severe pneumonia and induced cytokine storm.Effective therapeutic approaches in addition to the vaccines and drugs under development are hence greatly sought after.Therapies harnessing stem cells and their derivatives have been established by basic research for their versatile capacity to specifically inhibit inflammation due to pneumonia and prevent alveolar/pulmonary fibrosis while enhancing antibacterial/antiviral immunity,thus significantly alleviating the severe clinical conditions of pneumonia.In recent clinical trials,mesenchymal stem cells have shown effectiveness in reducing COVID-19-associated pneumonia morbidity and mortality;positioning these cells as worthy candidates for combating one of the greatest challenges of our time and shedding light on their prospects as a nextgeneration therapy to counter future challenges.  相似文献   
9.
10.
Adaptive seamless designs combine confirmatory testing, a domain of phase III trials, with features such as treatment or subgroup selection, typically associated with phase II trials. They promise to increase the efficiency of development programmes of new drugs, for example, in terms of sample size and/or development time. It is well acknowledged that adaptive designs are more involved from a logistical perspective and require more upfront planning, often in the form of extensive simulation studies, than conventional approaches. Here, we present a framework for adaptive treatment and subgroup selection using the same notation, which links the somewhat disparate literature on treatment selection on one side and on subgroup selection on the other. Furthermore, we introduce a flexible and efficient simulation model that serves both designs. As primary endpoints often take a long time to observe, interim analyses are frequently informed by early outcomes. Therefore, all methods presented accommodate interim analyses informed by either the primary outcome or an early outcome. The R package asd , previously developed to simulate designs with treatment selection, was extended to include subgroup selection (so-called adaptive enrichment designs). Here, we describe the functionality of the R package asd and use it to present some worked-up examples motivated by clinical trials in chronic obstructive pulmonary disease and oncology. The examples both illustrate various features of the R package and provide insights into the operating characteristics of adaptive seamless studies.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号